Patents Assigned to Pfizer
  • Squalene synthetase inhibitors
    Patent number: 5965553
    Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, Alzheimer's agents or anti-acne agents.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: October 12, 1999
    Assignee: Pfizer Inc.
    Inventors: Andrew S. Bell, Ernest S. Hamanaka, Cheryl M. Hayward, Douglas A. Scully, Blanda Stammen
  • Polycyclic ether antibiotic having anthelmintic, anticoccidial and growth promotant activity
    Patent number: 5965445
    Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Streptomyces sp. ATCC 55028. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, as a growth promotant in cattle and swine, and as an anthelmintic in mammals, particularly in dogs, cats, sheep, cattle and swine.
    Type: Grant
    Filed: March 11, 1992
    Date of Patent: October 12, 1999
    Assignee: Pfizer Inc.
    Inventors: Walter P. Cullen, John P. Dirlam, Hiroshi Maeda, Junsuke Tone
  • Indole carbamates as leukotriene antagonists
    Patent number: 5965745
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 AND R.sup.2 are as defined, useful in the treatment of asthma, rheumatoid arthritis, osteoarthritis, bronchitis, chronic obstructive airways diseases, psoriasis, allergic rhinitis, atopic dermatitis, shock, and other inflammatory diseases and for blocking the leucotriene D4 receptor, pharmaceutical compositions containing such compounds and methods of blocking leucotriene D4 receptors using such compositions.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: October 12, 1999
    Assignee: Pfizer Inc
    Inventors: Matthew F. Brown, Anthony Marfat
  • Anthelmintic milbemycins and avermectins
    Patent number: 5962659
    Abstract: Novel compounds of formula (I): ##STR1## wherein R.sup.1 is hydrogen or optionally protected hydroxy; R.sup.2 is alkoxy, optionally protected hydroxy, oxo or optionally O-substituted oximino; R.sup.3 is hydrogen, optionally protected hydroxy,or a group 4'-(.alpha.-L-oleandrosyl)-.alpha.-L-oleandrosyloxy or .alpha.-L-oleandrosyloxy wherein the terminal hydroxy group is optionally protected; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are the same or different and each is hydrogen or an organic radical; and R.sup.8 is an optionally substituted amino or imino group such as optionally O-substituted oxyimino, optionally N-substituted hydrazone, or optionally N-substituted semicarbazone; are useful in the treatment of helminthiasis in humans and animals.
    Type: Grant
    Filed: November 29, 1991
    Date of Patent: October 5, 1999
    Assignee: Pfizer, Inc.
    Inventors: Geoffrey Harold Baker, Roderick John Dorgan, David Owen Morgan, Peter Robin Shelley, Simon Edward Blanchflower
  • 2,3 Disubstituted- (5,6)-heteroarylfused-pyrimidine-4-ones
    Patent number: 5962457
    Abstract: The present invention relates to novel compounds of the formula I, described above, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: October 5, 1999
    Assignee: Pfizer Inc.
    Inventors: Bertrand L. Chenard, Willard M. Welch, Jr.
  • Corticotropin releasing factor antagonists
    Patent number: 5962479
    Abstract: Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.16 and R.sub.17 are as defined in the description, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment of CNS and stress-related disorders.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: October 5, 1999
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng Liang Chen
  • Substituted indazole derivatives
    Patent number: 5958953
    Abstract: The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein the broken line in formula I indicates a single or double bond, and wherein R, R.sub.1, X.sub.1 and X.sub.2 are as defined herein. The invention further relates to pharmaceutical compositions containing the compounds of formula I, and to methods of inhibiting phosphodiesterase type IV or the production of tumor necrosis factor in a mammal by administering the compounds of formula I to said mammal.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: September 28, 1999
    Assignee: Pfizer Inc
    Inventor: Anthony Marfat
  • Substituted pyrazoles as CRF antagonists
    Patent number: 5958948
    Abstract: The compounds of the formula wherein A, R.sub.1, R.sub.3, X.sub.1, Y and Z are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: September 28, 1999
    Assignee: Pfizer, Inc.
    Inventors: Gene M. Bright, Willard M. Welch, Jr.
  • Process for preparing sildenafil
    Patent number: 5955611
    Abstract: A process for the preparation of a compound of formula (I): ##STR1## which comprises cyclization of a compound of formula (II): ##STR2##
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: September 21, 1999
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Albert Shaw Wood
  • Expression plasmids for improved production of heterologous protein in bacteria
    Patent number: 5955297
    Abstract: Promoter-ribosome binding site (rbs) expression elements of general utility for high level heterologous gene expression; plasmids carrying said promoter-rbs expression elements and encoding genetic information for direct high level expression in bacteria of heterologous proteins, especially plasmids carrying a gene coding for prorennin or mammalian growth hormones; methods for their construction, including the use of synthetic linkers to provide desirable functional properties thereto; recombinant microorganisms comprising said plasmids; expression of said bacterial produced heterologous proteins by said recombinant microorganisms; and demonstration of the activities of the thus-produced proteins.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: September 21, 1999
    Assignee: Pfizer Inc.
    Inventor: Arthur E. Franke
  • Pyrrolidinyl hydroxamic acid compounds and their production process
    Patent number: 5952369
    Abstract: A compound of formula (I) ##STR1## and its pharmaceutically acceptable salt, wherein A is hydrogen or OY, wherein Y is a hydroxy protecting group; Ar is phenyl optionally substituted with one or more substituents selected from halo, hydroxy, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, CF.sub.3, C.sub.1 -C.sub.4 alkoxy-C.sub.1 -C.sub.4 alkyloxy and carboxy-C.sub.1 -C.sub.4 alkyloxy;X is phenyl, naphthyl, biphenyl, indanyl, benzofuranyl, benzothiophenyl, 1-tetralone-6-yl,C.sub.1 -C.sub.4 alkylenedioxy, pyridyl, furyl and thienyl these groups optionally being substituted with up to three substituents selected from halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, NO.sub.2, CF.sub.3 and SO.sub.2 CH.sub.3 ; andR is hydrogen, C.sub.1 -C.sub.4 alkyl or a hydroxy protecting group.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: September 14, 1999
    Assignee: Pfizer Inc
    Inventor: Fumitaka Ito
  • Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
    Patent number: 5952322
    Abstract: A method of preventing non-cardiac tissue damage resulting from ischemia and/or hypoxia, comprising administering to a patient in need of such treatment an effective amount of an glycogen phosphorylase inhibitor.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 14, 1999
    Assignee: Pfizer Inc.
    Inventors: Dennis J. Hoover, William H. Martin, Judith L. Treadway, W. Ross Tracey
  • Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
    Patent number: 5952326
    Abstract: Compounds of the formula ##STR1## wherein R is an optionally substituted heteroaryl group such as 2-chromanyl, 2-pyridyl or 5-fluoro-2-benzothiazoyl;X is O, S or (CH.sub.2).sub.m ;R.sup.1 is phenyl or pyridyl, optionally substituted by one or more (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, carboxy or ?(C.sub.1 -C.sub.3)alkoxy!carbonyl groups;n is 0, 1 or 2;m is 1 or 2;Y and Y.sup.1 are taken together and are oxygen, or Y and Y.sup.1 are taken separately, Y is hydrogen and Y.sup.1 is hydroxy or an in vivo hydrolyzable acyloxy group;Z is CH.sub.2, NR.sup.2, O or S; andR.sup.2 is hydrogen or (C.sub.1 -C.sub.3)alkyl;are useful in the treatment of asthma, arthritis and related diseases mediated by leukotrienes.
    Type: Grant
    Filed: December 10, 1997
    Date of Patent: September 14, 1999
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Anthony Marfat, Lawrence S. Melvin, Jr.
  • Adamantyl substituted oxindoles as pharmaceutical agents
    Patent number: 5948781
    Abstract: This invention relates to a method of treating cancer by administering a compound of the formula wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, E.sup.1, E.sup.2, p, Het' and Het" are defined as indicated in the specification.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: September 7, 1999
    Assignee: Pfizer Inc
    Inventors: Joseph P. Lyssikatos, Robert A. Volkmann
  • Method of preventing allograft rejection
    Patent number: 5948813
    Abstract: A method for suppressing the rejection of allogeneic transplants in a mammal, including a human, comprising administering to said mammal an effective amount of the compound of the formula ##STR1## wherein n, A, B, R.sup.1 and R.sup.2 are as defined above, or the pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: September 7, 1999
    Assignee: Pfizer Inc.
    Inventors: Henry J. Showell, Elora J. Weringer
  • Pharmaceutical tablet
    Patent number: D413972
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: September 14, 1999
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Pharmaceutical tablet
    Patent number: D413973
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: September 14, 1999
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Pharmaceutical tablet
    Patent number: D414259
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: September 21, 1999
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Pharmaceutical tablet
    Patent number: D414551
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: September 28, 1999
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Pharmaceutical tablet
    Patent number: D414552
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: September 28, 1999
    Assignee: Pfizer Inc.
    Inventor: Robert Burrows